Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
Denmark: COPSAC, Copenhagen Prospective Study of Childhood Asthma, researchers in Copenhagen, Denmark, noted that a higher risk...
Read Full NewsClinicians continue prescribing antibiotics unnecessarily despite growing evidence supporting shorter, targeted, and reassessed treatment strategies.
Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.
Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.
The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.
1.
Integrating MRD in Myeloma: Guidance for Therapy Escalation and De-escalation
2.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
3.
Top Cancer Centers; Phase III Win in Prostate Cancer; Screening Recs for Anal Cancer
4.
Mammo Responsibility Increases Screening; Opioids for Pain Related to Cancer? Ignored CRC Signs.
5.
In MDS at Lower Risk, Novel Therapy Diminished Transfusion Dependency.
1.
A Novel Gemcitabine-Releasing Intravesical System for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer
2.
Epigenetics and Resistance: Mechanisms in Histone Methylation-Targeted Therapies
3.
Unlocking the Potential of Onivyde: A New Hope for Cancer Treatment
4.
Precision Medicine and Genomics: Harnessing Longitudinal Data Modeling to Decode Cancer Progression
5.
Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
3.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
4.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
5.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge